End-of-day quote
Shanghai S.E.
23:00:00 25/06/2024 BST
|
5-day change
|
1st Jan Change
|
27.95
CNY
|
+0.79%
|
|
-8.66%
|
-43.54%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
5,889
|
5,324
|
7,940
|
7,654
|
4,322
|
-
|
-
|
Enterprise Value (EV)
1 |
5,889
|
5,324
|
7,940
|
7,654
|
4,322
|
4,322
|
4,322
|
P/E ratio
|
18.1
x
|
17.6
x
|
21.2
x
|
18.4
x
|
9.39
x
|
7.2
x
|
6.32
x
|
Yield
|
-
|
-
|
-
|
2.16%
|
3.85%
|
4.68%
|
5.72%
|
Capitalization / Revenue
|
1.32
x
|
-
|
-
|
0.84
x
|
0.4
x
|
0.31
x
|
0.27
x
|
EV / Revenue
|
1.32
x
|
-
|
-
|
0.84
x
|
0.4
x
|
0.31
x
|
0.27
x
|
EV / EBITDA
|
16.3
x
|
-
|
-
|
10.6
x
|
4.44
x
|
3.71
x
|
3.11
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
3.43
x
|
-
|
-
|
2.68
x
|
1.37
x
|
1.21
x
|
1.09
x
|
Nbr of stocks (in thousands)
|
139,729
|
140,998
|
154,694
|
154,619
|
154,619
|
-
|
-
|
Reference price
2 |
42.15
|
37.76
|
51.33
|
49.50
|
27.95
|
27.95
|
27.95
|
Announcement Date
|
14/04/21
|
27/04/22
|
26/04/23
|
26/04/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
4,466
|
-
|
-
|
9,081
|
10,768
|
13,920
|
15,719
|
EBITDA
1 |
361
|
-
|
-
|
719.7
|
973.5
|
1,165
|
1,392
|
EBIT
1 |
292.3
|
-
|
-
|
522.1
|
568.9
|
741.6
|
871.4
|
Operating Margin
|
6.54%
|
-
|
-
|
5.75%
|
5.28%
|
5.33%
|
5.54%
|
Earnings before Tax (EBT)
1 |
300.5
|
-
|
-
|
522.7
|
608.9
|
761.1
|
911.4
|
Net income
1 |
251.1
|
300.5
|
363.4
|
414.4
|
460.2
|
601
|
684.7
|
Net margin
|
5.62%
|
-
|
-
|
4.56%
|
4.27%
|
4.32%
|
4.36%
|
EPS
2 |
2.333
|
2.150
|
2.417
|
2.683
|
2.975
|
3.883
|
4.425
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
1.071
|
1.075
|
1.308
|
1.600
|
Announcement Date
|
14/04/21
|
27/04/22
|
26/04/23
|
26/04/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
31.8%
|
-
|
-
|
15.2%
|
14.6%
|
16.8%
|
17.3%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
4.23%
|
6.26%
|
6.68%
|
7.06%
|
Assets
1 |
-
|
-
|
-
|
9,797
|
7,351
|
8,997
|
9,699
|
Book Value Per Share
2 |
12.30
|
-
|
-
|
18.50
|
20.40
|
23.10
|
25.50
|
Cash Flow per Share
2 |
2.270
|
-
|
-
|
6.630
|
7.440
|
6.940
|
8.100
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
14/04/21
|
27/04/22
|
26/04/23
|
26/04/24
|
-
|
-
|
-
|
Last Close Price
27.95
CNY Average target price
52.06
CNY Spread / Average Target +86.27% Consensus |
1st Jan change
|
Capi.
|
---|
| -43.54% | 595M | | -40.02% | 13.51B | | -45.40% | 9.23B | | -25.00% | 6.9B | | -6.51% | 6.05B | | +83.43% | 4.87B | | -4.23% | 4.55B | | +2.24% | 4.34B | | -20.22% | 4.44B | | -18.33% | 2.59B |
Other Drug Retailers
|